eMedicine Specialties > Gastroenterology > Liver
Alcoholic Fatty Liver: Treatment & Medication
Updated: Sep 15, 2008
- Overview
- Differential Diagnoses & Workup
- Treatment & Medication
- Follow-up
Treatment
Medical Care
- No specific medical treatment is needed for patients with alcoholic fatty liver. Steatosis usually resolves within 2 weeks of discontinuing alcohol.
- Abstinence and adequate diet are the mainstays in therapy for alcohol-induced steatosis.
- Bed rest has no proven benefit.
- Anabolic steroids may be detrimental.
- Management of patients with alcoholism and fatty liver often requires recognition and treatment of alcohol withdrawal.
- These patients may have deficiencies of vitamins, minerals, and trace elements. Adequate replacement of these deficiencies should be a part of management.
- Although alcohol-induced hyperhomocysteinemia (which has been associated with endoplasmic reticulum stress leading to apoptosis and up-regulation of lipid synthesis) and its correction by betaine have been studied in animal models, no definite role of the use of betaine in alcoholic fatty liver in humans is available.
Consultations
- Offer alcohol rehabilitation to all patients, with an understanding of the addictive problem of alcoholism.
- Counsel patients on the detrimental effects of alcohol on the current liver problem and the likely progression to a more advanced form of liver disease with continued alcohol use.
Diet
- No specific dietary restrictions are needed in patients with simple steatosis.
- Protein-calorie malnutrition is a common finding for patients with ALD and is associated with major complications observed with cirrhosis. Consequently, recognizing and understanding the significance of malnutrition in these patients is very important.
Medication
No drug therapy is indicated for patients with alcoholic fatty liver unless the patient has alcoholic hepatitis.
More on Alcoholic Fatty Liver |
| Overview: Alcoholic Fatty Liver |
| Differential Diagnoses & Workup: Alcoholic Fatty Liver |
Treatment & Medication: Alcoholic Fatty Liver |
| Follow-up: Alcoholic Fatty Liver |
| References |
| « Previous Page | Next Page » |
References
Ballard H, Bernstein M, Farrar JT. Fatty liver presenting as obstructive jaundice. Am J Med. Feb 1961;30:196-201. [Medline].
Uchida T, Kao H, Quispe-Sjogren M, et al. Alcoholic foamy degeneration--a pattern of acute alcoholic injury of the liver. Gastroenterology. Apr 1983;84(4):683-92. [Medline].
Ashley MJ, Olin JS, le Riche WH, et al. Morbidity in alcoholics. Evidence for accelerated development of physical disease in women. Arch Intern Med. Jul 1977;137(7):883-7. [Medline].
Becker U, Deis A, Sørensen TI, et al. Prediction of risk of liver disease by alcohol intake, sex, and age: a prospective population study. Hepatology. May 1996;23(5):1025-9. [Medline].
Bellentani S, Saccoccio G, Masutti F, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med. Jan 18 2000;132(2):112-7. [Medline].
Caraceni P, Ryu HS, Subbotin V, et al. Rat hepatocytes isolated from alcohol-induced fatty liver have an increased sensitivity to anoxic injury. Hepatology. Apr 1997;25(4):943-9. [Medline].
Chedid A, Mendenhall CL, Gartside P, et al. Prognostic factors in alcoholic liver disease. VA Cooperative Study Group. Am J Gastroenterol. Feb 1991;86(2):210-6. [Medline].
Christoffersen P, Braendstrup O, Juhl E, et al. Lipogranulomas in human liver biopsies with fatty change. A morphological, biochemical and clinical investigation. Acta Pathol Microbiol Scand [A]. 1971;79(2):150-8. [Medline].
Crabb DW, Galli A, Fischer M, et al. Molecular mechanisms of alcoholic fatty liver: role of peroxisome proliferator-activated receptor alpha. Alcohol. Aug 2004;34(1):35-8. [Medline].
Dam-Larsen S, Franzmann MB, Christoffersen P, et al. Histological characteristics and prognosis in patients with fatty liver. Scand J Gastroenterol. Apr 2005;40(4):460-7. [Medline].
Dawson DA. Beyond black, white and Hispanic: race, ethnic origin and drinking patterns in the United States. J Subst Abuse. 1998;10(4):321-39. [Medline].
Day CP, Yeaman SJ. The biochemistry of alcohol-induced fatty liver. Biochim Biophys Acta. Nov 17 1994;1215(1-2):33-48. [Medline].
Diehl AM. Alcoholic liver disease: natural history. Liver Transpl Surg. May 1997;3(3):206-11. [Medline].
Fletcher LM. Alcohol and iron: one glass of red or more?. J Gastroenterol Hepatol. Nov 1996;11(11):1039-41. [Medline].
Fromenty B, Grimbert S, Mansouri A, et al. Hepatic mitochondrial DNA deletion in alcoholics: association with microvesicular steatosis. Gastroenterology. Jan 1995;108(1):193-200. [Medline].
Fuchs CS, Stampfer MJ, Colditz GA, et al. Alcohol consumption and mortality among women. N Engl J Med. May 11 1995;332(19):1245-50. [Medline].
Grant BF, Dufour MC, Harford TC. Epidemiology of alcoholic liver disease. Semin Liver Dis. Feb 1988;8(1):12-25. [Medline].
Guzman M, Castro J. Zonal heterogeneity of the effects of chronic ethanol feeding on hepatic fatty acid metabolism. Hepatology. Nov 1990;12(5):1098-105. [Medline].
Helander A, Carlsson AV, Borg S. Longitudinal comparison of carbohydrate-deficient transferrin and gamma-glutamyl transferase: complementary markers of excessive alcohol consumption. Alcohol Alcohol. Jan 1996;31(1):101-7. [Medline].
Hoyumpa AM Jr, Greene HL, Dunn GD, et al. Fatty liver: biochemical and clinical considerations. Am J Dig Dis. Dec 1975;20(12):1142-70. [Medline].
Iversen K, Christoffersen P, Poulsen H. Epithelioid cell granulomas in liver biopsies. Scand J Gastroenterol Suppl. 1970;7:61-7. [Medline].
Jepsen P, Vilstrup H, Mellemkjaer L, et al. Prognosis of patients with a diagnosis of fatty liver--a registry-based cohort study. Hepatogastroenterology. Nov-Dec 2003;50(54):2101-4. [Medline].
Keegan A, Martini R, Batey R. Ethanol-related liver injury in the rat: a model of steatosis, inflammation and pericentral fibrosis. J Hepatol. Nov 1995;23(5):591-600. [Medline].
Klingman GI, McGoodall C. Urinary epinephrine and levarterenol excretion during acute sublethal alcohol intoxication in dogs. J Pharmacol Exp Ther. Nov 1957;121(3):313-8. [Medline].
Koff RS, Dienstag JL. Extrahepatic manifestations of hepatitis C and the association with alcoholic liver disease. Semin Liver Dis. Feb 1995;15(1):101-9. [Medline].
Leevy CM. Fatty liver: a study of 270 patients with biopsy proven fatty liver and review of the literature. Medicine (Baltimore). Sep 1962;41:249-76. [Medline].
Lindros KO. Alcoholic liver disease: pathobiological aspects. J Hepatol. 1995;23 Suppl 1:7-15. [Medline].
Litten RZ, Allen JP, Fertig JB. Gamma-glutamyltranspeptidase and carbohydrate deficient transferrin: alternative measures of excessive alcohol consumption. Alcohol Clin Exp Res. Dec 1995;19(6):1541-6. [Medline].
Loft S, Olesen KL, Døssing M. Increased susceptibility to liver disease in relation to alcohol consumption in women. Scand J Gastroenterol. Dec 1987;22(10):1251-6. [Medline].
Lumeng L, Crabb DW. Genetic aspects and risk factors in alcoholism and alcoholic liver disease. Gastroenterology. Aug 1994;107(2):572-8. [Medline].
MacSween RN, Burt AD. Histologic spectrum of alcoholic liver disease. Semin Liver Dis. Aug 1986;6(3):221-32. [Medline].
Matloff DS, Selinger MJ, Kaplan MM. Hepatic transaminase activity in alocholic liver disease. Gastroenterology. Jun 1980;78(6):1389-92. [Medline].
Mavrelis PG, Ammon HV, Gleysteen JJ, et al. Hepatic free fatty acids in alcoholic liver disease and morbid obesity. Hepatology. Mar-Apr 1983;3(2):226-31. [Medline].
McMullen MR, Pritchard MT, Wang Q, et al. Early growth response-1 transcription factor is essential for ethanol-induced fatty liver injury in mice. Gastroenterology. Jun 2005;128(7):2066-76. [Medline].
Mezey E. Alcoholic liver disease. Prog Liver Dis. 1982;7:555-72. [Medline].
Montull S, Pares A, Bruguera M, et al. Alcoholic foamy degeneration in Spain. Prevalence and clinico-pathological features. Liver. Apr 1989;9(2):79-85. [Medline].
Morgan MY, Camilo ME, Luck W, et al. Macrocytosis in alcohol-related liver disease: its value for screening. Clin Lab Haematol. 1981;3(1):35-44. [Medline].
Morgan MY, Sherlock S. Sex-related differences among 100 patients with alcoholic liver disease. Br Med J. Apr 9 1977;1(6066):939-41. [Medline].
Morgan MY, Sherlock S, Scheuer PJ. Acute cholestasis, hepatic failure, and fatty liver in the alcoholic. Scand J Gastroenterol. 1978;13(3):299-303. [Medline].
Nakano M, Worner TM, Lieber CS. Perivenular fibrosis in alcoholic liver injury: ultrastructure and histologic progression. Gastroenterology. Oct 1982;83(4):777-85. [Medline].
Naveau S, Perlemuter G, Chaillet M, et al. Serum leptin in patients with alcoholic liver disease. Alcohol Clin Exp Res. Aug 2006;30(8):1422-8. [Medline].
Orrego H, Israel Y, Blake JE, et al. Assessment of prognostic factors in alcoholic liver disease: toward a global quantitative expression of severity. Hepatology. Nov-Dec 1983;3(6):896-905. [Medline].
Oshita M, Hayashi N, Kasahara A, et al. Increased serum hepatitis C virus RNA levels among alcoholic patients with chronic hepatitis C. Hepatology. Nov 1994;20(5):1115-20. [Medline].
Rashid A, Wu TC, Huang CC, et al. Mitochondrial proteins that regulate apoptosis and necrosis are induced in mouse fatty liver. Hepatology. Apr 1999;29(4):1131-8. [Medline].
Rubin E, Lieber CS. Alcohol-induced hepatic injury in nonalcoholic volunteers. N Engl J Med. Apr 18 1968;278(16):869-76. [Medline].
Savolainen VT, Liesto K, Mannikko A, et al. Alcohol consumption and alcoholic liver disease: evidence of a threshold level of effects of ethanol. Alcohol Clin Exp Res. Oct 1993;17(5):1112-7. [Medline].
Schmucker DL, Wang RK. Age-related changes in liver drug-metabolizing enzymes. Exp Gerontol. 1980;15(5):423-31. [Medline].
Seitz HK, Yu Y, Simanowski UA, et al. Effect of age and gender on in vivo ethanol elimination, hepatic alcohol dehydrogenase activity, and NADP availability in F344 rats. Res Exp Med. 1992;192:205–12.
Sorensen HT, Mellemkjaer L, Jepsen P. Risk of cancer in patients hospitalized with fatty liver: a Danish cohort study. J Clin Gastroenterol. Apr 2003;36(4):356-9. [Medline].
Teli MR, Day CP, Burt AD. Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver [see comments]. Lancet. Oct 14 1995;346(8981):987-90. [Medline].
Tilg H, Diehl AM. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med. Nov 16 2000;343(20):1467-76. [Medline].
Venkatesan S, Ward RJ, Peters TJ. Effect of chronic ethanol feeding on the hepatic secretion of very-low- density lipoproteins [published erratum appears in Biochim Biophys Acta 1988 May 22;960(2):257]. Biochim Biophys Acta. May 2 1988;960(1):61-6. [Medline].
Yersin B, Nicolet JF, Dercrey H, et al. Screening for excessive alcohol drinking. Comparative value of carbohydrate-deficient transferrin, gamma-glutamyltransferase, and mean corpuscular volume. Arch Intern Med. Sep 25 1995;155(17):1907-11. [Medline].
Ylikahri RH. Ethanol-induced changes in hepatic alpha-glycerophosphate and triglyceride concentrations in normal and thyroxine-treated rats. Metabolism. Dec 1970;19(12):1036-45. [Medline].
You M, Considine RV, Leone TC, et al. Role of adiponectin in the protective action of dietary saturated fat against alcoholic fatty liver in mice. Hepatology. Sep 2005;42(3):568-77. [Medline].
Zakim D. Effect of ethanol on hepatic acyl-coenzyme A metabolism. Arch Biochem Biophys. Aug 1965;111(2):253-6. [Medline].
Zieve L. Jaundice, hyperlipemia and hemolytic anemia: a heretofore unrecognized syndrome associated with alcoholic fatty liver and cirrhosis. Ann Intern Med. Mar 1958;48(3):471-96. [Medline].
Further Reading
Keywords
alcoholic fatty liver, alcoholic steatosis, alcoholism, fatty liver, alcohol-related fatty liver, alcoholic liver disease, alcohol-related liver disease, simple steatosis, alcohol-related steatosis, fatty acids, alcoholic complications, alcohol-induced steatosis, alcohol-induced fatty liver
Treatment & Medication: Alcoholic Fatty Liver